Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting.
Rizzo MM, Bluthgen MV, Recondo G, Naveira M, Perfetti A, Rizzi F, Kuzminin A, Faura V, Cerini M, Videla A, Silva C, Lupinacci L, Minatta N. Rizzo MM, et al. Among authors: recondo g. Int J Clin Oncol. 2021 Jun;26(6):1057-1064. doi: 10.1007/s10147-021-01896-x. Epub 2021 Mar 14. Int J Clin Oncol. 2021. PMID: 33715058
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Motzer RJ, et al. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Access of patients with breast and lung cancer to chemotherapy treatment in public and private hospitals in the city of Buenos Aires.
Recondo G, Cosacow C, Cutuli HJ, Cermignani L, Straminsky S, Naveira M, Pitzzu M, De Ronato G, Nacuzzi G, Taetti G, Corsico S, Berrueta M, Colucci G, Gibbons L, Gutierrez L, García-Elorrio E. Recondo G, et al. Int J Qual Health Care. 2019 Nov 30;31(9):682-690. doi: 10.1093/intqhc/mzz047. Int J Qual Health Care. 2019. PMID: 31125084
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
Martin C, Lupinacci L, Perazzo F, Bas C, Carranza O, Puparelli C, Kowalyszyn R, Magri I, Varela M, Richardet E, Vera K, Foglia S, Jerez I, Aman E, Martinengo G, Batagelj E, Dri A, Pilnik N, Roa GM, Mando P, Tsou F, Recondo G, Cayol F, Flores M, Sena S, Bagnes C, Waisberg FD, Minatta JN, Rizzo M. Martin C, et al. Among authors: recondo g. Clin Lung Cancer. 2020 Sep;21(5):e380-e387. doi: 10.1016/j.cllc.2020.02.014. Epub 2020 Feb 26. Clin Lung Cancer. 2020. PMID: 32213298
Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America.
Martin C, Cuello M, Barajas O, Recondo G, Aruachan S, Perroud H, Sena S, Bonilla C, Orlandi F, Berutti S, Garcia Cocco V, Gomez A, Korbenfeld E, Zapata M, Cundom J, Orellana E, Goncalves S, Reinhold F. Martin C, et al. Among authors: recondo g. Mol Clin Oncol. 2022 Jan;16(1):6. doi: 10.3892/mco.2021.2439. Epub 2021 Nov 12. Mol Clin Oncol. 2022. PMID: 34881026 Free PMC article.
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Lobefaro R, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar-Nana F, Ponce S, Dal Maso A, Spotti M, Mielgo-Rubio X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier J, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Planchard D, Mezquita L. Riudavets M, et al. Among authors: recondo g. Eur J Cancer. 2022 May;167:142-148. doi: 10.1016/j.ejca.2022.02.014. Epub 2022 Mar 17. Eur J Cancer. 2022. PMID: 35307254
Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP).
Raez LE, Arrieta O, Chamorro DF, Soberanis-Piña PD, Corrales L, Martín C, Cuello M, Samtani S, Recondo G, Mas L, Zatarain-Barrón ZL, Ruíz-Patiño A, García-Robledo JE, Ordoñez-Reyes C, Jaller E, Dickson F, Rojas L, Rolfo C, Rosell R, Cardona AF. Raez LE, et al. Among authors: recondo g. Front Oncol. 2022 Jul 12;12:904800. doi: 10.3389/fonc.2022.904800. eCollection 2022. Front Oncol. 2022. PMID: 35903685 Free PMC article.
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar Nana F, Ponce S, Albarrán-Artahona V, Dal Maso A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier JB, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Mezquita L, Planchard D. Riudavets M, et al. Among authors: recondo g. Clin Lung Cancer. 2024 May;25(3):233-243.e8. doi: 10.1016/j.cllc.2023.11.007. Epub 2023 Nov 22. Clin Lung Cancer. 2024. PMID: 38105153
87 results